DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR ESTIMATION OF BALOFLOXACIN IN BULK AND TABLET DOSAGE FORM
Keywords:
Balofloxacin, RP-HPLC, Validation, Stability indicating, DegradationAbstract
Objective: The objective of the method was to develop a simple, rapid, efficient, cost effective and reproducible, stability indicating (RP-HPLC) Reverse Phase High Performance Liquid Chromatography method for the estimation of Balofloxacin in bulk and tablet dosage form.
Methods: The RP-HPLC analysis was carried out on an Enable C18 G column with a mobile phase of Potassium dihydrogen orthophosphate (pH adjusted to 2.5 with 0.1 M ortho phosphoric acid) and Acetonitrile in the ratio of 75:25% v/v. The analyte was detected at 293 nm using PDA detector. The method was validated in terms of linearity, accuracy, precision, LOD (Limit of Detection), LOQ (Limit of Quantification) and robustness as per ICH guidelines.
Results: The method was found to be linear in the range of 10-120 µg/ml. Limit of detection and limit of quantitation was found to be 0.793 and 2.405 µg/ml respectively. Recovery was found to be in the range 100.268- 101.077 % and precision less than 2%. The developed method was successfully applied for the estimation of Balofloxacin in marketed tablet formulation (Baloforce TAB) and percentage assay was found to be 101.690 %. Forced degradation studies were performed under different conditions. The drug was degraded in acidic, basic, oxidative, UV light and sunlight conditions. The peaks of degraded products were well resolved from the actual drug. The results obtained prove that the developed method is a stability indicating method.
Conclusion: The developed RP-HPLC method was simple, rapid, accurate, precise and stability indicating for the estimation of Balofloxacin in bulk and tablet dosage form.
Downloads
References
Bakshi M, Singh S. Development of Validated Stability-Indicating Assay Methods-Critical Review. J Pharm Biomed Anal 2002;28:1011-40.
Stability I, Rockville MD, J. FDA. Guidance for of Drug Substances and Drug Products (Draft Guidance). J Drug Administration 1998.
ICH, Validation of Analytical Procedures:Text and Methodology Q2 (R1), in:Proceedings of the International Conference on Harmonization. IFPMA Geneva 2005.
http://www.drug2day.com/index.php/drug/display/965.
http://www.drugsandpharmacology.blogspot.in//03/balofloxacin.html 2013.
Nyola NK, Govindasamy J. Estimation of Balofloxacin in Active Pharmaceutical Ingridents and Pharmaceutical Formulations by Different Methods. Novel Sci Int J of Pharm Sci 2012;1(7) 425-9.
Potnuri NR. et al. Development and Validation of a Reverse Phase-HPLC Method for the Determination of Balofloxacin in Bulk and Pharmaceutical Dosage Forms. J Drug Invention Today 2012;4(12) 655-8.
Reddy SA, Sekhar KC. Development and Validation of Analytical Method for Estimation of Balofloxacin in Bulk and Pharmaceutical Dosage Form. J of Global Trends in Pharm Sci 2012;3(2):647-55.
Thumar PM, Patel VB. Development and Validation of Analytical Method for Estimation of Balofloxacin in Bulk and Pharmaceutical Dosage Form. Int J of Pharm Tech Res 2011;3(4):1938-41.
Seetharaman R, et al. Determination of Balofloxacin in Pharmaceutical Formulations by Zero, First, Second Order Derivative Spectroscopic Methods. Int J Res Pharm Sci 2011;2(3):438-43.
Pai S, Nayak S. Development of a New Spectroscopic Method for Determination of Balofloxacin in Tablet Dosage Form. Int J of Scientific Res 2013;2(7):76-7.
Jain PS, Redasani VK, Patil VK, Patil MS, Gawad JB. Reversed-Phase TLC/ Densitometry Method for Estimation of Balofloxacin in Bulk and in Tablet Dosage Form. Int J of Adv Res 2013;1(7):257-62.
Ravisankar P, et al. A Novel Validated RP-HPLC Method for The Determination of Balofloxacin in Bulk and Pharmaceutical Dosage Forms. Int J of Pharmacy and Industrial Res 2013;3(2):127-36.
Pai SP. Spectrophotometric Determination of Balofloxacin by Ion-Pair Complexation Reaction in The Bulk and Tablet Dosage Forms. Asian J of Pharm and Clinical Res 2013;1(1):22-4.
Tang Q, et al. Study of The Fragmentation Patterns of Nine Fluoroquinolones by Tandem Mass Spectrometry. J Analytical Letters 2012;45(1):43-50.
Wang L, et al. Luminescence Enhancement Effect for The Determination of Balofloxacin with Balofloxacin–Europium (III)–Sodium Dodecylbenzene Sulfonate System. J of Luminescence 2009;129(1):90-4.
Bian Z, et al. High Performance Liquid Chromatography–Electrospray Ionization Mass Spectrometric Determination of Balofloxacin in Human Plasma and its Pharmacokinetics. J of Chromatography B 2007;850(1):68-73.
Wang DW, et al. Determination of Balofloxacin in Plasma by HPLC-Fluorescence and its Pharmacokinetics in Rats. J-China Pharmaceutical University 2004;35(2):160-3.
Chu ZJ, Dong YB, Yang FH, Wang L. Determination of The Content of Balofloxacin in Human Plasma by RP-HPLC Method and its Application in Therapeutic Drug Monitoring. J Pharm Care and Res 2008;8(3):223-5.
Yin S, et al. Determination of Balofloxacin in Human Urine by RP-HPLC with Fluorescence Detection. J of Shenyang Pharm University 2007;11:691-4.
Kozawa O, et al. Comparative Study of Pharmacokinetics of Two New Fluoroquinolones, Balofloxacin and Grepafloxacin, in Elderly Subjects. J Antimicrobial Agents and Chemotherapy 1996;40(12):2824-8.
Nakagawa T, Ishigai M., Hiramatsu Y, Kinoshita H, Ishitani Y, Ohkubo K, Okazaki A. Determination of The New Fluoroquinolone Balofloxacin and its Metabolites in Biological Fluids by High Performance Liquid Chromatography. J Arzneimittelforschung 1995;45:716-8.
Marutani K, Matsumoto M., Otabe Y, Nagamuta M, Tanaka K, Miyoshi A, et al. Reduced Phototoxicity of a Fluoroquinolone Antibacterial Agent with a Methoxy Group at the 8 Position in Mice Irradiated with Long-Wavelength UV Light. Antimicrob. J Agents Chemother 1993;37:2217-23.